In 2022, ASTRO-Myovant Sciences-Pfizer Alliance announced a New Combination (Relugolix-Radiation) Therapy Challenge. The target budget for each individual project grant was up to $500,000. Information about this Challenge and awardees is available here.
Collaborations across the biomedical research ecosystem are critical to advance medicine. In the 2017 ASTRO Strategic Plan, the ASTRO Board prioritized elevating the profile of the field and retaining and fostering the research talent entering the field. It further described a vision in which cancer care would be characterized by the significant role of radiation oncology in this evolution of care and would be well understood by the House of Medicine. Key innovations in cancer medicine are driven by partnerships between basic and clinical researchers, and industry. ASTRO encourages more radiation oncology researchers serving as PIs for industry supported studies.
The ASTRO Advancing-Medicine-Together Scientific Challenges (“Challenges”) program aims to introduce and catalyze new collaborative research opportunities for the ASTRO membership, and to facilitate radiation oncology leadership in scientific discovery and engagement with industry partners.
Value to ASTRO Members:
Value to Partners: